Scarica l'app Stockscreener
4.855
8.28%
0.385
Precedente Chiudi:
$4.47
Aprire:
$4.68
Volume 24 ore:
798.03K
Relative Volume:
0.34
Capitalizzazione di mercato:
$799.20M
Reddito:
$361.51M
Utile/perdita netta:
$102.18M
Rapporto P/E:
8.1269
EPS:
0.5974
Flusso di cassa netto:
$112.21M
1 W Prestazione:
+17.48%
1M Prestazione:
+47.11%
6M Prestazione:
+21.61%
1 anno Prestazione:
+541.23%
Intervallo 1D:
$4.59
$4.875
Intervallo di 1 settimana:
$4.16
$4.875
Portata 52W:
$0.6701
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.855 | 735.82M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 53.59B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 43.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.54 | 40.35B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.17 | 31.98B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
559.63 | 23.93B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Form 144 IRONWOOD PHARMACEUTICALS For: 7 July By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Proposed Common stock sale for IRWD (NASDAQ: IRWD) via Morgan Stanley Smith Barney - Stock Titan
Price to earnings forward of Ironwood Pharmaceuticals, Inc. – NASDAQ:IRWD - TradingView
Ironwood Pharmaceuticals stock follows its own business case. IRWD trades on Nasdaq. - AD HOC NEWS
Ironwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings Momentum - Yahoo Finance
Price to book forward of Ironwood Pharmaceuticals, Inc. – NASDAQ:IRWD - TradingView
IRWD Forecast — Price Target — Prediction for 2027 - TradingView
Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda - Barchart.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (BX:I76) - TradingView
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (SWB:I76) - TradingView
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (MUN:I76) - TradingView
I76 Forecast — Price Target — Prediction for 2027 - TradingView
5 Small Drug Stocks to Invest in Amid a Biotech Comeback - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ironwood Pharmaceuticals StockAnalyst snapshot and sector review at week’s end - AD HOC NEWS
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ironwood Pharmaceuticals Inc - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Institutional Confidence - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Director Julie Mchugh Sells 21,571 Shares of Ironwood Pharmaceuticals Inc (IRWD) - GuruFocus
Ironwood Pharmaceuticals Inc (IRWD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting - Stock Titan
Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4 - Stock Titan
Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant - Stock Titan
Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares - Stock Titan
[144] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
Ironwood Pharmaceuticals (IRWD) Jefferies London Healthcare Conference 2024 Summary - Quartr
Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026 - TradingView
Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash - Stock Titan
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - MSN
Ironwood Pharmaceuticals (IRWD) Tops Healthcare Sector with Stro - GuruFocus
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026? - Yahoo Finance
· SEC Filing - MLQ.ai
IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Chart - ChartMill
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead - TradingView
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price, News, Quote & History - Yahoo Finance
Ironwood Pharmaceuticals Expands Linzess Use and Drives Record Q1 2026 Revenue - asatunews.co.id
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McHugh Julie | Director |
Jun 16 '26 |
Sale |
3.73 |
21,571 |
80,460 |
250,749 |
1.43%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):